September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Immune responses of Behçet’s disease patients with or without recurrent uveitis after infliximab treatment
Author Affiliations & Notes
  • Masaru Takeuchi
    Ophthalmology, National Defense Medical College, Tokorozawa, Saitama, Japan
  • Yoko Karasawa
    Ophthalmology, National Defense Medical College, Tokorozawa, Saitama, Japan
  • Kohzou Harimoto
    Ophthalmology, National Defense Medical College, Tokorozawa, Saitama, Japan
  • Yutaka Sakurai
    Ophthalmology, National Defense Medical College, Tokorozawa, Saitama, Japan
  • Tomohito Sato
    Ophthalmology, National Defense Medical College, Tokorozawa, Saitama, Japan
  • Rachel R. Caspi
    Immunology, National Eye Institute, Bethesda, Maryland, United States
  • Masataka Ito
    Developmental Anatomy and Regenerative Biology, National Defense Medical College, Tokorozawa, Japan
  • Footnotes
    Commercial Relationships   Masaru Takeuchi, None; Yoko Karasawa, None; Kohzou Harimoto, None; Yutaka Sakurai, None; Tomohito Sato, None; Rachel Caspi, None; Masataka Ito, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1891. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Masaru Takeuchi, Yoko Karasawa, Kohzou Harimoto, Yutaka Sakurai, Tomohito Sato, Rachel R. Caspi, Masataka Ito; Immune responses of Behçet’s disease patients with or without recurrent uveitis after infliximab treatment. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1891.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Infliximab is a chimeric IgG1 monoclonal antibody that blocks binding of TNFα to its receptor, and various studies have shown remarkably beneficial effects of infliximab in the treatment of Behçet’s disease (BD)-associated uveitis. However, recurrent uveitis was observed in some BD patients after initiation of infliximab treatment. It has been found that peripheral blood mononuclear cells (PBMCs) produce proinflammatory cytokines, and Th1-, Th2-, and Th17-related cytokines when stimulated with IRBP. In this study, we examined the quantitative changes of proinflammatory cytokines, and Th1-, Th2-, and Th17-related cytokines produced by PBMCs from BD patients with uveitis before and after treatment with infliximab when stimulated with retinal self-antigen. Furthermore, we compared cytokine production between BD patients with recurrent uveitis during infliximab treatment and those in whom recurrent uveitis was not observed after initiation of infliximab treatment.

Methods : PBMCs were obtained from 4 BD patients with recurrent uveitis (BD-recurrent uveitis group) and 4 BD patients with remitted uveitis (BD-remitted uveitis group) after initiation of infliximab before and 1 week after infliximab infusion. PBMCs were cultured in vitro with various concentrations of IRBP, and levels of IL-1β, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-25, IL-33, IL-31, soluble CD40 ligand (sCD40L), IFN-γ, and TNFα in cultures were measured.

Results : Levels of IL-1β, IL-4, IL-17A, IL-17F, IL-21, IL-22, IL-31, IFN-γ, sCD40L, and TNFα were higher, with a significant difference for IL-17F in BD-recurrent uveitis group than in BD-remitted uveitis group. Only the level of IL-10 was higher in the remission group than in recurrence group. After infliximab infusion, levels of cytokines except for IL-4, IL-22, and sCD40L were not apparently reduced in BD-recurrent uveitis group. On the other hand, levels of IL-6, IL-10, IL-17F, IL-22, IL-31, IFN-γ, and TNFα were lower, with significant differences for IL-17F, IL-22, and sCD40L, in BD-remitted uveitis group.

Conclusions : Th-related cytokines by PBMCs upon IRBP stimulation were suppressed after infliximab infusion preferentially in BD patients without recurrent uveitis. Measurement of these cytokines by IRBP-stimulated PBMCs would be a clue to evaluate quantitatively the efficacy of infliximab treatment for uveitis in BD patients.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×